Table 5.
Primary-culture | Fourth-passage | Fourth-passage | ||||
RA-SFB | RA-SFB | RA-SFB | ||||
Isolated cells | Isolated cells | Conventionally passaged cells | ||||
(n = 9 patients) | (n = 3 patients) | (n = 6 patients) | ||||
Antigen | Percent | MFI | Percent | MFI | Percent | MFI |
Thy-1 (CD90; mAb AS02) | 73.8 ± 9.6 | 109 ± 20 | 86.6 ± 4.6 | 41 ± 7# | 85.9 ± 4.3 | 95 ± 17x |
MHC-I | a77.2 ± 8.1 | 130 ± 54 | 99.2 ± 0.2# | 117 ± 48 | 97.4 ± 1.4# | 175 ± 78 |
MHC-II | a65.8 ± 12.3 | 223 ± 84 | 4.7 ± 2.9# | 59 ± 25 | 4.8 ± 2.4# | 80 ± 21 |
Aminopeptidase N (CD13) | 84.8 ± 5.9 | 444 ± 226 | 97.2 ± 1.6 | 108 ± 49 | 97.9 ± 1.2# | 236 ± 95 |
VCAM-1 (CD106) | c17.5 ± 9.8 | 122 ± 42 | n.d. | n.d. | c0.6 ± 0.1 | 21 ± 5# |
Prolyl-4-hydroxylase | 84.8 ± 2.9 | 164 ± 45 | 98.7 ± 0.8# | 164 ± 62 | 98.3 ± 0.7# | 189 ± 82 |
Vimentin | a93.2 ± 1.5 | 592 ± 290 | 99.5 ± 0.4# | 717 ± 126 | 99.7# | 325 |
Procollagen I | a44.8 ± 13.0 | 25 ± 2 | 92.7 ± 2.8# | 25 ± 12 | 91.0 ± 4.0# | 28 ± 5 |
Procollagen III | a50.0 ± 14.3 | 26 ± 3 | 94.1 ± 1.8# | 21 ± 12 | 90.2 ± 5.2# | 22 ± 4 |
c-Fos | a57.4 ± 14.0 | 20 ± 2 | 63.5 ± 16.4 | 10 ± 5 | 95.0 ± 0.6#x | 17 ± 2 |
c-Jun | b42.5 ± 14.0 | 21 ± 5 | n.d. | n.d. | d42.1 ± 12.0 | 9 ± 2# |
Jun-D | a53.0 ± 14.8 | 21 ± 4 | 68.1 ± 13.2 | 11 ± 5 | 93.0 ± 1.3#x | 18 ± 3 |
Data presented as means ± SEM. MFI, Mean fluorescence intensity; mAb, monoclonal antibody; MHC, major histocompatibility complex; VCAM-1, vascular adhesion molecule-1; n.d., not determined. For vimentin expression in conventionally passaged fourth-passage RA-SFB, the median is shown because of a large deviation from the mean. Significant differences between groups are indicated in bold. #P ≤ 0.05 Mann–Whitney U test versus primary-culture RA-SFB. xP ≤ 0.05 Mann–Whitney U test versus fourth-passage RA-SFB (isolated cells). an = 7 RA patients. bn = 6 RA patients. cn = 5 RA patients. dn = 4 RA patients.